Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy

Figure 1 Downregulation of signal transducer and activator 3 by reactivating Src homology region 2 domain-containing phosphatase 1 is an important anti-tumor property of sorafenib. Signal transducer and activator 3 (STAT3) is a key regulator that connects extrinsic carcinogenic stimulations and oncogenic signaling pathways (A). Sorafenib and its derivatives can inhibit STAT3 and STAT3-associated signaling pathways by reactivating SHP-1, a negative regulator of STAT3, in hepatocellular carcinoma cells (B).